CN108524509A - A kind of pharmaceutical composition for treating hypertension - Google Patents
A kind of pharmaceutical composition for treating hypertension Download PDFInfo
- Publication number
- CN108524509A CN108524509A CN201710125903.6A CN201710125903A CN108524509A CN 108524509 A CN108524509 A CN 108524509A CN 201710125903 A CN201710125903 A CN 201710125903A CN 108524509 A CN108524509 A CN 108524509A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- hypertension
- pharmaceutically acceptable
- present
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition for treating hypertension, described pharmaceutical composition includes the compound or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier of following formula：
Description
Technical field
The present invention relates to field of medicaments, and specifically, the present invention relates to a kind of pharmaceutical compositions for treating hypertension.
Background technology
Hypertensive Population has become the big Health Killer of people from modern metropolitan cities, must cause our attention.High blood
The sick major determinant human body blood of pressure.It can promote ductus arteriosus wall to be hardened, tube chamber stenosis --- i.e. usually described " artery sclerosis, it is high
Blood pressure diseases can accelerate if complication with diabetes, aggravate blood vessel damage, so that the state of an illness is deteriorated rapidly, it should active treatment.As the modern times cure
Continuous development, the theory of hypertension therapeutic are not solely restricted to the treatment of hypertension also in continuous development and change
On Treatment of Hypertension, a series of complication are the even more important sides of hypertension therapeutic caused by effective prevention and treatment hypertension
Face.Now to the treatment of hypertension, the long-term survival rate for improving patient is even more important content, otherwise, blood pressure reduces
, and the survival rate of hypertensive patient cannot improve or even can reduce the survival rate of patient, this also allows for Treatment of Hypertension and loses
Most basic meaning.It can be said that in existing antihypertensive drugs, there are no meeting, present hypertension therapeutic theory is very ideal
Drug come out.
Invention content
The purpose of the present invention is to provide a kind of pharmaceutical compositions for treating hypertension.
In order to achieve the object of the present invention, the present invention provides a kind of pharmaceutical composition for treating hypertension, the medicine group
Close compound of the object comprising following formula or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier：
Preferably, various pharmaceutically acceptable dosage forms can be made in described pharmaceutical composition.
The present invention also provides purposes of the compound in the drug for preparing treatment hypertension, the compound has following knot
Structure：
Drug of the present invention can be used for treating or alleviating hypertension symptom and related symptoms, obstacle and disease,
Suitable for a plurality of types of hypertensive patients, can efficiently, the adjusting blood pressure of safety, slow release maintains more stable blood medicine
Concentration and longer action time, have the advantages that toxic side effect reduce, take it is more convenient.
Specific implementation mode
It will be appreciated by those skilled in the art that the concept and specific implementation mode disclosed in description above can be easy to
With the basis for making an amendment or designing the other embodiment for implementing the identical purpose of the present invention.What those skilled in the art also will be understood that
It is that these equivalent embodiments are not detached from the spirit and scope of the present invention illustrated in the appended claims.
The characterization of 1 the compounds of this invention of experimental example
1H NMR(400MHz,DMSO-d6)δ1.82-2.10(7H,m),2.18(6H,s),2.35-2.50(2H,m),3.0-
3.1(2H,m),3.31-3.39(2H,m),3.35(3H,s),3.61-3.74(2H,m),4.36(2H,t),6.99(1H,d),
7.97(1H,d),8.01(1H,dt),8.39(1H,d),8.45(1H,d),8.97(1H,s)。
Therapeutic effect of 2 the compounds of this invention of experimental example for hypertension
SPF grades of SD rats 40, half male and half female are taken to leave and take 10 rats (half male and half female) at random and be used as Normal group,
Remaining 30 rat is as modeling group.After modeling group rat is with 10% chloraldurate (0.4ml/100g) intraperitoneal injection of anesthesia
Rat, which lies on the back, is fixed on operating table, cuts off abdomen chaeta, 5% iodophor disinfection, and 75% alcohol takes off iodine, covers hole towel.Just along abdomen
Center line operate notch open abdominal cavity, by sterile working, careful blunt separation goes out left renal artery, penetrates chorda serica chirurgicalis sterilis, diameter
It is close to be placed in parallel with arteria renalis blood vessel long axis for the acupuncture needle of 0.25mm, is taken out after tightening the arteria renalis and acupuncture needle with chorda serica chirurgicalis sterilis
Go out acupuncture needle, unilateral renal artery stenosis, offside kidney and artery is as a result caused not to touch.Rats in normal control group is removed and does not ligature kidney
Outside artery, remaining surgical procedure is same as above, as sham-operation group.Penicillin (3 × 10 is injected intraperitoneally in postoperative continuous 3d4U/d) pre-
Anti- infection.Each group animal is normally raised.
Modeling rat 30, Etomidate 100mgkg are taken after modeling 10w-1Intraperitoneal injection of anesthesia, BP-100A are complete certainly
Dynamic rat non-invasive blood pressure measuring system tail sleeve method measures each modeling rat blood pressure, as Hypertensive Rats blood pressure number before administration
Value.3 groups, respectively model control group, Captopril tablets group, target compound group are divided by blood pressure values, it is every group 10, female
It is male fifty-fifty.Its blood pressure is measured with method anesthesia Normal group (sham-operation group) rat tail sleeve method, as normal rat blood before administration
Press numerical value.
Each administration group according to dosage gastric infusion, Captopril tablets 0.003gkg after grouping-1, target compound 0.003g
kg-1.Sham-operation group, model control group give isometric distilled water with method gavage.1 time a day, continuous 4w.As a result it see the table below.
Claims (3)
1. a kind of pharmaceutical composition for treating hypertension, which is characterized in that described pharmaceutical composition include following formula compound or
Its pharmaceutically acceptable salt and pharmaceutically acceptable carrier：
2. the pharmaceutical composition for the treatment of hypertension according to claim 1, which is characterized in that described pharmaceutical composition can be with
Various pharmaceutically acceptable dosage forms are made.
3. purposes of the compound in the drug for preparing treatment hypertension, which is characterized in that the compound has having structure：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710125903.6A CN108524509A (en) | 2017-03-05 | 2017-03-05 | A kind of pharmaceutical composition for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710125903.6A CN108524509A (en) | 2017-03-05 | 2017-03-05 | A kind of pharmaceutical composition for treating hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108524509A true CN108524509A (en) | 2018-09-14 |
Family
ID=63488609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710125903.6A Withdrawn CN108524509A (en) | 2017-03-05 | 2017-03-05 | A kind of pharmaceutical composition for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108524509A (en) |
-
2017
- 2017-03-05 CN CN201710125903.6A patent/CN108524509A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2707089C2 (en) | Combined composition | |
| RU2010129825A (en) | MATERIALS AND METHODS FOR TREATMENT OF PATHOLOGICAL PROLIFERATION OF EYE VESSELS | |
| RU2009119258A (en) | METHOD FOR TREATING INFLAMMATORY DISEASES OF THE INTESTINE | |
| MX2019008482A (en) | Medical treatment comprising enteral administration of edaravone. | |
| CN103977010A (en) | Compound xylazine injection for dogs and preparation method thereof | |
| CN105596324A (en) | Application of naringenin to preparation of drugs for preventing and/or treating aortic dissection | |
| CN108524509A (en) | A kind of pharmaceutical composition for treating hypertension | |
| RU2016144695A (en) | COMPLEX OF SITAGLIPTIN TANNA | |
| CN101732399B (en) | Three-herb tea for lowering pressure | |
| RU2014150946A (en) | METHOD FOR LOWER WEIGHT | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN106581088A (en) | Drug for treating coronary heart diseases | |
| ES2668943T3 (en) | Pharmaceutical composition to treat premature ejaculation and method of treatment of premature ejaculation | |
| RU2557882C1 (en) | Method of carrying out premedication in planned surgery | |
| KR101391551B1 (en) | Pharmaceutical composition for prevention and treatment of heart failure and combined formulation including the same | |
| RU2010122438A (en) | ANTIVIRAL AGENT FOR PREVENTION AND TREATMENT OF tick-borne encephalitis | |
| CN112516285B (en) | Pharmaceutical composition for preventing or treating ischemia/reperfusion injury and application thereof | |
| CN102552295B (en) | Medicine for treating internal and external hemorrhoids and preparation method thereof | |
| CN100431532C (en) | Breviscapine and borneol constituted composite injection formulation and preparation method thereof | |
| UA66689A (en) | Method for maintaining hemodynamics in spinal anesthesia for cesarean section | |
| CN102048721A (en) | Injection preparation | |
| CN106619701A (en) | Western medicine composition for treating coronary heart disease and preparation method thereof | |
| CN106562965A (en) | Compound medicinal preparation for treating renal hypertension | |
| CN105481844A (en) | Pharmaceutical composition for the treatment of hypertension | |
| Tarkase | Spinal Anaesthesia With 0.5% Hyperbaric Ropivacaine and 0.5% Hyperbaric Bupivacaine: A Comparative Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180914 |
|
| WW01 | Invention patent application withdrawn after publication |